首页> 美国卫生研究院文献>other >In Vitro Induced Regulatory T Cells Are Unique from Endogenous Regulatory T Cells and Effective at Suppressing Late Stages of Ongoing Autoimmunity
【2h】

In Vitro Induced Regulatory T Cells Are Unique from Endogenous Regulatory T Cells and Effective at Suppressing Late Stages of Ongoing Autoimmunity

机译:体外诱导的调节性T细胞是内源性调节性T细胞所独有的可有效抑制正在进行的自身免疫的晚期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Strategies to boost the numbers and functions of regulatory T cells (Tregs) are currently being tested as means to treat autoimmunity. While Tregs have been shown to be effective in this role, strategies to manipulate Tregs to effectively suppress later stages of ongoing diseases need to be established. In this study, we evaluated the ability of TGF-β-induced Tregs (iTregs) specific for the major self-antigen in autoimmune gastritis to suppress established autoimmune gastritis in mice. When transferred into mice during later stages of disease, iTregs demethylated the Foxp3 promoter, maintained Foxp3 expression, and suppressed effector T cell proliferation. More importantly, these iTregs were effective at stopping disease progression. Untreated mice had high numbers of endogenous Tregs (enTregs) but these were unable to stop disease progression. In contrast, iTregs, were found in relatively low numbers in treated mice, yet were effective at stopping disease progression, suggesting qualitative differences in suppressor functions. We identified several inhibitory receptors (LAG-3, PD-1, GARP, and TNFR2), cytokines (TGF-β1 and IL12p35), and transcription factors (IRF4 and Tbet) expressed at higher levels by iTregs compared to enTregs isolated form mice with ongoing disease, which likely accounts for superior suppressor ability in this disease model. These data support efforts to use iTregs in therapies to treat establish autoimmunity, and show that iTregs are more effective than enTregs at suppressing inflammation in this disease model.
机译:目前正在测试增加调节性T细胞(Tregs)数量和功能的策略,作为治疗自身免疫的手段。尽管已显示Treg在这种作用中是有效的,但仍需要建立操纵Treg的策略来有效抑制疾病进展的后期阶段。在这项研究中,我们评估了自身免疫性胃炎中主要自身抗原特异性的TGF-β诱导的Tregs(iTregs)抑制小鼠中已建立的自身免疫性胃炎的能力。当在疾病的后期转移到小鼠体内时,iTregs使Foxp3启动子脱甲基,维持Foxp3表达,并抑制效应T细胞增殖。更重要的是,这些iTreg可有效阻止疾病进展。未经治疗的小鼠具有高数量的内源性Treg(enTreg),但它们无法阻止疾病的进展。相反,在处理过的小鼠中发现iTregs的数量相对较少,但在阻止疾病进展方面是有效的,表明抑制子功能在质量上存在差异。我们鉴定了iTregs较从enTregs分离的小鼠中以较高水平表达的几种抑制性受体(LAG-3,PD-1,GARP和TNFR2),细胞因子(TGF-β1和IL12p35)和转录因子(IRF4和Tbet)。进行性疾病,可能在这种疾病模型中具有较高的抑制能力。这些数据支持在治疗中使用iTreg来治疗自身免疫的努力,并显示iTreg在抑制该疾病模型中的炎症方面比enTreg更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号